Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX
Valuace
30
Růst
83
Zdraví
48
Cena
$ 415.16
Dnes
+2.44 (0.56%)
Souhrn
Výkazy
Ukazatele
Profil
Držitelé
Návštěvnost webu
Konkurence
Zprávy společnosti
Kapitalizace
106.5B
Obrat
12B
Zisk
4B
Aktiva
25B
Dluh
2B
ROE
0%
ROA
0%
PE
29
PS
10
Cena 1R
363-520
⌀ Cena
437.26
Dividenda
0.0(0.0%)
Čtvrtletní 10-Q
10-Q
Celoroční 10-K
8-K
Nadcházející oznámení zisků
12-02-2026
Poslední dividenda

Profil

Společnost Vertex Pharmaceuticals Incorporated, biotechnologická společnost, se zabývá vývojem a komercializací terapií pro léčbu cystické fibrózy. Společnost prodává SYMDEKO/SYMKEVI, ORKAMBI a KALYDECO k léčbě pacientů s cystickou fibrózou, kteří mají specifické mutace v jejich genu pro regulaci převodní vodivosti cystické fibrózy; a TRIKAFTA k léčbě pacientů s CF 6 let nebo starších, kteří mají alespoň jednu mutaci F508del. Jeho potrubí obsahuje VX-864 pro léčbu deficitu AAT, který je v klinické studii fáze 2; VX-147 pro léčbu fokální segmentální glomerulosklerózy zprostředkované APOL1 nebo FSGS a dalších závažných onemocnění ledvin, které jsou v klinické studii fáze 2; VX- 880, léčba diabetu typu 1, která je v klinické studii fáze 1/2; VX-548, inhibitor NaV1.8 pro léčbu akutní, neuropatické, muskuloskeletální bolesti, která fáze 2 klinického hodnocení; a CTX001 závažného stupně SCD a TDT při léčbě, který je součástí fáze 3 klinického hodnocení. Společnost prodává své výrobky především specializovaným lékárnám a specializovaným distributorům ve Spojených státech, jakož i specializovaným distributorům a maloobchodním řetězcům a nemocnicím a klinikám v mezinárodním měřítku. Spolupracuje se společnostmi Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; a Skyhawk Therapeutics, Inc.; a Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Německo a X-Chem, Inc. Vertex Pharmaceuticals Incorporated byla založena v 1 1989 a má sídlo v Bostonu, Massachusetts.
Sektor
Healthcare
Odvětví
Biotechnology
Počet zaměstnanců
6100
Založení
1991-07-24
Adresa
50 Northern Avenue
CEO
Reshma Kewalramani FASN,

Podobné společnosti

$ 848.98
- $ 3.01
$ 455.55
- $ 21.06
$ 92.21
+ $ 0.01
$ 50.17
+ $ 0.51
$ 46.75
+ $ 0.12

Zahraniční články

Výsledovka

Rozvaha

Peněžní toky

Výsledovka

Výsledovka
Rozvaha
Peněžní toky
V miliardách (USD)
Revenue TTM 2025202420232022202120202019201820172016201520142013201220112010
Total Revenues12.0412.0711.029.878.937.576.214.163.052.491.701.030.581.211.531.410.14
Cost of Revenues1.651.811.531.261.080.900.740.550.410.280.210.130.060.130.280.080.01
Gross Profit10.3910.279.498.617.856.675.473.622.642.211.490.910.521.081.251.330.13
Revenue 4-20253-20252-20251-20254-20243-20242-20241-20244-20233-2023
Total Revenues3.233.082.962.772.912.772.652.692.522.48
Cost of Revenues0.470.410.410.360.420.390.370.340.370.32
Gross Profit2.762.662.562.412.492.382.272.342.152.16
Operating Income TTM 2025202420232022202120202019201820172016201520142013201220112010
R&D Expenses0.000.000.003.162.543.051.831.751.421.321.051.000.860.920.810.710.64
Selling General & Admin Expenses0.000.000.001.140.940.840.770.660.560.500.430.380.310.360.440.400.19
Depreciation & Amortization0.210.210.210.180.040.010.330.260.070.060.060.060.060.050.040.040.03
Total Operating Expenses6.125.519.724.783.493.892.602.411.971.821.481.371.161.281.241.110.83
Operating Income4.274.76-0.234.314.312.782.861.200.640.120.01-0.47-0.69-0.900.000.11-0.70
Operating Income TTM 4-20253-20252-20251-20254-20243-20242-20241-20244-20233-2023
R&D Expenses0.000.000.000.000.000.000.000.000.820.81
Selling General & Admin Expenses0.000.000.000.000.000.000.000.000.370.26
Depreciation & Amortization0.050.050.050.050.050.050.050.050.060.04
Total Operating Expenses1.461.481.411.781.461.265.791.211.191.07
Operating Income1.301.191.150.631.031.12-3.511.140.961.04
Net Income TTM 2025202420232022202120202019201820172016201520142013201220112010
Interest Income0.490.490.600.610.140.000.020.060.000.000.000.000.000.000.000.000.00
Interest Expense0.010.010.030.040.050.060.060.060.030.060.080.080.070.020.010.040.02
Other Expense0.38-0.120.480.07-0.08-0.050.260.20-0.03-0.350.00-0.01-0.02-0.780.00-0.12-0.04
IBT4.644.640.254.384.232.733.121.390.60-0.02-0.07-0.56-0.73-0.98-0.010.06-0.75
Income Tax Expense0.690.690.780.760.910.390.410.22-1.49-0.110.020.030.01-0.290.040.020.02
Net Income3.953.95-0.543.623.322.342.711.182.100.26-0.11-0.56-0.74-0.45-0.110.03-0.75
Net Income TTM 4-20253-20252-20251-20254-20243-20242-20241-20244-20233-2023
Interest Income0.120.130.120.120.130.130.160.180.180.17
Interest Expense0.000.000.000.000.000.010.010.010.010.01
Other Expense0.030.110.130.100.110.110.120.140.160.14
IBT1.331.301.280.731.141.22-3.391.281.151.18
Income Tax Expense0.140.220.250.080.220.180.200.180.180.14
Net Income1.191.081.030.650.911.05-3.591.100.971.04
Per Share Data TTM 2025202420232022202120202019201820172016201520142013201220112010
EPS$0.00$0.00$0.00$14.05$12.97$9.09$10.44$4.58$8.25$1.06$-0.46$-2.31$-3.14$-1.98$-0.50$0.14$-3.77
EPS Diluted$0.00$0.00$0.00$13.89$12.82$9.01$10.29$4.51$8.09$1.04$-0.46$-2.31$-3.14$-1.98$-0.50$0.14$-3.77
Shares Outstanding0.250.260.260.260.260.260.260.260.250.250.240.240.240.220.210.200.20
Diluted Shares Outstanding0.260.260.260.260.260.260.260.260.260.250.240.240.240.220.210.210.20
Per Share Data TTM 4-20253-20252-20251-20254-20243-20242-20241-20244-20233-2023
EPS$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$3.76$4.01
EPS Diluted$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$3.71$3.97
Shares Outstanding0.250.260.260.260.260.260.260.260.260.26
Diluted Shares Outstanding0.260.260.260.260.260.260.260.260.260.26
Current Assets TTM 202420232022202120202019201820172016201520142013201220112010
Cash And Equivalents4.584.5710.3710.506.805.993.112.651.671.180.710.630.570.490.480.24
Short Term Investments1.221.550.850.270.730.670.700.520.420.250.330.760.900.830.490.79
Total Cash & ST Investments5.806.1211.2210.787.526.663.813.172.091.431.041.391.471.320.971.03
Accounts Receivable1.661.611.561.441.140.890.630.410.280.200.180.070.090.140.180.01
Inventory0.911.210.740.460.350.280.170.120.110.080.060.030.010.030.110.00
Other Current Assets0.580.670.620.070.190.310.210.070.060.020.010.060.020.020.980.01
Total Current Assets8.949.6014.1412.689.017.834.613.702.481.761.361.551.591.591.331.06
Current Assets 3-20252-20251-20254-20243-20242-20241-20244-20233-20232-2023
Cash And Equivalents4.944.974.674.575.244.589.1610.3711.1110.15
Short Term Investments1.351.411.531.551.291.221.010.8511.9311.24
Total Cash & ST Investments6.296.386.206.126.525.8010.1711.2211.9311.24
Accounts Receivable1.951.891.811.611.751.661.791.561.541.56
Inventory1.631.501.361.211.080.910.810.740.690.60
Other Current Assets0.710.650.640.670.450.580.510.620.540.48
Total Current Assets10.5710.4310.019.609.808.9413.2914.1414.7013.87
Long-Term Assets TTM 202420232022202120202019201820172016201520142013201220112010
Net Property, Plant & Equipment1.772.581.451.111.090.960.750.810.790.700.700.720.700.430.130.07
Goodwill1.091.091.091.091.401.401.400.050.050.050.050.040.030.030.030.03
Intangible Assets0.840.830.840.600.400.400.400.000.030.280.280.030.110.660.660.52
Long-Term Investments4.405.112.600.000.000.000.000.000.020.020.000.000.010.000.000.00
Other Long-Term Assets0.911.000.801.420.990.680.370.180.190.100.110.000.000.040.050.05
Total Long-Term Assets11.1912.948.595.474.423.933.712.541.061.131.140.790.731.170.870.67
Total Assets20.1322.5322.7318.1513.4311.758.326.253.552.892.502.342.322.762.201.73
Long-Term Assets 3-20252-20251-20254-20243-20242-20241-20244-20233-20232-2023
Net Property, Plant & Equipment3.022.652.632.582.511.771.491.451.431.45
Goodwill1.091.091.091.091.091.091.091.091.091.09
Intangible Assets0.430.440.440.830.830.840.830.840.600.60
Long-Term Investments5.725.655.165.114.704.394.382.601.701.36
Other Long-Term Assets1.101.081.011.000.990.920.880.800.480.44
Total Long-Term Assets14.2913.6112.8712.9412.4411.1910.638.597.036.48
Total Assets24.8624.0422.8822.5322.2420.1323.9222.7321.7320.35
Current Liabilities TTM 202420232022202120202019201820172016201520142013201220112010
Accounts Payable0.330.410.360.300.200.160.090.110.070.060.070.070.050.100.070.04
Short-Term Debt0.000.090.080.090.050.040.030.010.020.320.090.030.020.010.200.14
Other Current Liabilities3.092.692.831.881.461.171.020.040.47-0.450.330.250.310.290.410.23
Current Liabilities3.553.563.552.431.871.561.200.720.810.010.510.370.400.430.840.47
Current Liabilities 3-20252-20251-20254-20243-20242-20241-20244-20233-20232-2023
Accounts Payable4.030.440.450.410.400.330.350.360.380.36
Short-Term Debt0.000.000.000.090.000.000.000.080.000.00
Other Current Liabilities0.443.703.342.693.583.223.442.833.222.99
Current Liabilities4.484.143.783.563.973.553.803.553.603.35
Long-Term Liabilities TTM 202420232022202120202019201820172016201520142013201220112010
Long-Term Debt0.931.661.450.470.560.580.580.570.560.840.820.830.440.670.400.40
Capital Leases0.931.750.720.470.560.580.580.570.560.540.530.530.440.270.000.00
Def. Tax Liability0.000.000.000.000.000.00-0.09-0.080.010.130.110.020.030.280.240.16
Total Liabilities5.366.125.154.243.333.062.231.811.501.561.401.240.961.521.241.22
Long-Term Liabilities 3-20252-20251-20254-20243-20242-20241-20244-20233-20232-2023
Long-Term Debt1.831.531.651.661.700.930.721.451.491.54
Capital Leases1.831.531.651.751.700.930.720.720.740.77
Def. Tax Liability0.000.000.000.000.000.000.000.920.000.00
Total Liabilities7.546.866.386.126.615.365.375.155.214.88
Total Common Equity TTM 202420232022202120202019201820172016201520142013201220112010
Common Stock0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
Retained Earnings7.659.6110.146.523.200.86-1.85-2.99-5.12-5.37-5.26-4.71-3.97-3.52-3.41-3.44
Comprehensive Income0.020.13-0.010.000.02-0.070.000.00-0.010.020.000.000.000.000.000.00
Total Common Equity14.7716.4117.5813.9110.108.696.094.442.041.341.091.101.361.000.790.50
Total Common Equity 3-20252-20251-20254-20243-20242-20241-20244-20233-20232-2023
Common Stock0.000.000.000.000.000.000.000.000.260.26
Retained Earnings12.3711.2910.259.618.697.6511.2410.149.178.14
Comprehensive Income-0.06-0.100.070.130.030.020.02-0.010.00-0.04
Total Common Equity17.3217.1816.5016.4115.6314.7718.5517.5816.5115.47
Other TTM 202420232022202120202019201820172016201520142013201220112010
Total Debt0.931.750.810.560.560.580.580.570.560.840.820.830.440.670.400.54
Book Value14.7716.4117.5813.9110.108.696.094.442.041.341.091.101.361.230.970.50
Other 3-20252-20251-20254-20243-20242-20241-20244-20233-20232-2023
Total Debt0.000.000.000.000.000.000.000.000.000.00
Book Value17.3217.1816.5016.4115.6314.7718.5517.5816.5115.47
Cash Flow From Operating Activities TTM 2025202420232022202120202019201820172016201520142013201220112010
Net Income-0.493.95-0.543.623.322.342.711.182.090.09-0.08-0.59-0.74-0.69-0.050.04-0.75
Depreciation & Amortization0.210.210.210.180.150.130.110.110.070.060.060.060.060.050.040.040.03
Stock-Based Compensation0.690.000.700.580.490.440.430.360.330.290.240.230.180.130.110.130.10
Change Working Capital-0.76-1.20-0.51-0.270.34-0.11-0.05-0.070.240.020.00-0.09-0.01-0.01-0.01-0.19-0.06
Change In Accounts Receivable-0.11-0.35-0.10-0.08-0.36-0.27-0.22-0.23-0.11-0.07-0.03-0.100.010.050.04-0.170.00
Change In Accounts Payable-0.050.040.050.050.120.030.05-0.020.040.01-0.010.000.03-0.050.010.040.00
Change In Inventories-0.35-0.52-0.52-0.32-0.14-0.09-0.13-0.06-0.03-0.04-0.02-0.02-0.020.01-0.03-0.110.01
Other Non-cash Items0.831.180.00-0.040.10-0.01-0.22-0.180.060.510.010.010.000.750.140.140.00
Cash from Operations-0.940.000.003.544.132.643.251.571.270.840.24-0.37-0.51-0.050.270.14-0.64
Cash Flow From Operating Activities 4-20253-20252-20251-20254-20243-20242-20241-20244-20233-2023
Net Income1.191.081.030.650.911.05-3.591.100.971.04
Depreciation & Amortization0.060.050.050.050.050.050.050.050.060.04
Stock-Based Compensation0.160.190.170.170.170.180.150.190.210.13
Change Working Capital-0.950.15-0.13-0.27-0.560.16-0.240.13-0.840.19
Change In Accounts Receivable-0.10-0.06-0.02-0.170.07-0.050.14-0.250.02-0.01
Change In Accounts Payable0.04-0.040.010.030.010.07-0.030.00-0.030.01
Change In Inventories-0.08-0.13-0.15-0.17-0.15-0.18-0.11-0.08-0.07-0.10
Other Non-cash Items0.010.000.070.42-0.030.05-0.01-0.01-0.03-0.01
Cash from Operations0.000.000.000.000.000.000.000.000.231.27
Cash Flow From Investing Activities TTM 2025202420232022202120202019201820172016201520142013201220112010
Capital Expenditure-0.48-0.44-0.30-0.20-0.20-0.24-0.26-0.08-0.10-0.26-0.06-0.05-0.05-0.05-0.07-0.09-0.04
Acquisitions-0.050.000.000.00-0.300.08-0.42-1.150.00-0.160.00-0.08-0.010.000.00-0.060.00
Investments-5.58-6.40-7.70-3.82-0.74-0.61-0.45-0.58-0.52-0.53-0.63-0.63-1.42-2.41-1.71-0.72-1.23
Sales of Investment2.445.914.470.930.920.500.810.570.430.370.761.071.562.351.371.021.28
Other Investing Activities-0.170.000.00-0.060.00-0.080.420.00-0.020.150.03-0.040.000.06-0.020.070.00
Cash from Investing-3.600.000.00-3.14-0.32-0.340.10-1.24-0.20-0.440.100.270.07-0.05-0.430.210.01
Cash Flow From Investing Activities 4-20253-20252-20251-20254-20243-20242-20241-20244-20233-2023
Capital Expenditure-0.15-0.10-0.15-0.04-0.09-0.07-0.07-0.07-0.12-0.04
Acquisitions0.000.000.000.000.000.000.000.00-0.060.00
Investments-1.23-1.35-2.17-1.65-2.16-1.13-1.55-2.60-1.02-0.41
Sales of Investment1.111.331.841.641.461.111.180.710.220.33
Other Investing Activities0.000.000.000.000.000.000.000.000.030.00
Cash from Investing0.000.000.000.000.000.000.000.00-0.89-0.12
Cash Flow From Financing Activities TTM 2025202420232022202120202019201820172016201520142013201220112010
Debt Repaid-0.050.000.00-0.04-0.09-0.05-0.04-0.04-0.03-0.32-0.09-0.02-0.08-0.08-0.02-0.250.00
Debt Issued0.221.750.940.290.090.020.050.050.040.040.110.020.47-0.150.290.110.54
Issuance of Common Stock0.130.000.000.130.190.100.260.340.290.340.070.190.270.270.190.120.03
Repurchase of Common Stock-0.77-2.02-1.58-0.43-0.17-1.56-0.74-0.19-0.350.000.000.000.000.000.000.000.00
Dividends Paid0.000.000.000.000.00-0.10-0.26-0.01-0.020.000.000.000.000.000.000.000.00
Other Financing Activities-0.300.000.00-0.230.000.130.280.020.040.040.160.020.300.000.000.000.39
Cash from Financing-1.000.000.00-0.56-0.07-1.48-0.510.13-0.070.070.130.190.500.180.17-0.120.43
Cash Flow From Financing Activities 4-20253-20252-20251-20254-20243-20242-20241-20244-20233-2023
Debt Repaid0.000.000.000.000.000.000.000.00-0.01-0.01
Debt Issued1.830.31-0.12-0.100.050.770.21-0.090.08-0.01
Issuance of Common Stock0.000.000.000.000.000.000.000.000.050.00
Repurchase of Common Stock-0.13-1.07-0.39-0.43-0.43-0.39-0.40-0.36-0.15-0.17
Dividends Paid0.000.000.000.000.000.000.000.000.000.00
Other Financing Activities0.000.000.000.000.000.000.000.000.000.02
Cash from Financing0.000.000.000.000.000.000.000.00-0.12-0.17
Cash position TTM 2025202420232022202120202019201820172016201520142013201220112010
Net Change in Cash-5.570.52-5.80-0.143.710.812.870.460.990.480.470.090.060.080.010.23-0.20
Closing Cash Balance4.585.094.5710.3710.516.805.993.122.661.671.180.710.630.570.490.480.24
Cash position 4-20253-20252-20251-20254-20243-20242-20241-20244-20233-2023
Net Change in Cash0.14-0.030.300.11-0.680.66-4.58-1.20-0.740.96
Closing Cash Balance5.094.954.984.694.575.254.589.1710.3711.12
Free Cash Flow TTM 2025202420232022202120202019201820172016201520142013201220112010
Free Cash Flow-1.433.19-0.793.283.932.412.991.491.170.750.18-0.41-0.62-0.170.200.05-0.67
Real Free Cash Flow-2.113.19-1.492.703.431.972.561.130.850.45-0.06-0.64-0.80-0.300.08-0.08-0.77
Free Cash Flow 4-20253-20252-20251-20254-20243-20242-20241-20244-20233-2023
Free Cash Flow0.351.140.930.780.491.30-3.831.060.121.23
Real Free Cash Flow0.190.940.760.610.321.12-3.980.87-0.091.10
Nacenění
Finance
Efektivita
Marže
Dividenda
Ostatní

Nacenění

Ukazatel Aktuální Historické Konkurence
P/E29.40.4-1.4
P/S9.7259.4
P/B6.712.35.2
P/FCF46.4121.5-1.5
Market cap$106.5$90.1
P/E (Price to Earnings Ratio) – Poměr ceny akcie k zisku za posledních 12 měsíců. Říká, kolik korun investor zaplatí za 1 korunu zisku. Např.: P/E = 15 znamená, že pokud akcie stojí 15 Kč, firma vydělala 1 Kč za poslední rok.

Finance

Ukazatel Aktuální Historické Srovnání
Debt to Assets0 %14.6 %0 %
Debt to Income46.4 %-17.5 %0 %
Debt to Free cash flow73.2 %97.5 %0 %
Interest expense percentage0.3 %25.7 %44.7 %
Current ratio2.4 10.1 0

Efektivita

Ukazatel Aktuální Historické Srovnání
ROE22.8 %-10.6 %0 %
ROA15.9 %0.4 %0 %
CapEx to Revenue3.6 %6.5 %0 %
RaD to Revenue0 %95.5 %0 %
ROEM1,973,508.2 882897.6

Marže

Ukazatel Aktuální Historické Srovnání
Gross margin86.3 %88 %68.7 %
Operating margin35.5 %-47.7 %35.5 %
Net margin32.8 %-49.3 %9.5 %

Dividenda

Ukazatel Aktuální Historické Srovnání
Dividend yield0 %0 %0 %
Dividend payout percentage0 %0.8 %0 %
Dividend yield (Dividendový výnos) ukazuje aktuální procentuální výnos z dividend vůči ceně akcie.

Ostatní

Ukazatel Aktuální Historické
Shares outstanding256.1 mil 244.2 mil
Employee count6.1 tis 1.9 tis

Placený obsah

Pro přístup na tuto stránku budete potřebovat placené členství.

Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.

Placený obsah

Pro přístup na tuto stránku budete potřebovat placené členství.

Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.

Placený obsah

Pro přístup na tuto stránku budete potřebovat placené členství.

Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.

Placený obsah

Pro přístup na tuto stránku budete potřebovat placené členství.

Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.

Placený obsah

Pro přístup na tuto stránku budete potřebovat placené členství.

Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.

Akciový screener
Kalendář zisků
Super investoři
Porovnání akcií
preloader